These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28989865)

  • 1. Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies.
    Cadamuro M; Morton SD; Strazzabosco M; Fabris L
    Transl Gastrointest Cancer; 2013 Jul; 2(3):130-144. PubMed ID: 28989865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness.
    Brivio S; Cadamuro M; Strazzabosco M; Fabris L
    World J Hepatol; 2017 Mar; 9(9):455-468. PubMed ID: 28396716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?
    Brivio S; Cadamuro M; Fabris L; Strazzabosco M
    J Clin Med; 2015 Dec; 4(12):2028-41. PubMed ID: 26703747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview.
    Brivio S; Cadamuro M; Fabris L; Strazzabosco M
    Gene Expr; 2018 Mar; 18(1):31-50. PubMed ID: 29070148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes.
    Li C; Bie L; Chen M; Ying J
    Explor Target Antitumor Ther; 2023; 4(6):1310-1327. PubMed ID: 38213535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium.
    Gentilini A; Pastore M; Marra F; Raggi C
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions.
    Massani M; Stecca T; Fabris L; Caratozzolo E; Ruffolo C; Furlanetto A; Morton S; Cadamuro M; Strazzabosco M; Bassi N
    Oncol Rep; 2013 Sep; 30(3):1143-8. PubMed ID: 23807641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
    Loosen SH; Roderburg C; Kauertz KL; Pombeiro I; Leyh C; Benz F; Vucur M; Longerich T; Koch A; Braunschweig T; Ulmer TF; Heidenhain C; Tacke F; Binnebösel M; Schmeding M; Trautwein C; Neumann UP; Luedde T
    J Hepatol; 2017 Oct; 67(4):749-757. PubMed ID: 28668580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.
    Cadamuro M; Stecca T; Brivio S; Mariotti V; Fiorotto R; Spirli C; Strazzabosco M; Fabris L
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1435-1443. PubMed ID: 28757170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.
    Clapéron A; Mergey M; Aoudjehane L; Ho-Bouldoires TH; Wendum D; Prignon A; Merabtene F; Firrincieli D; Desbois-Mouthon C; Scatton O; Conti F; Housset C; Fouassier L
    Hepatology; 2013 Dec; 58(6):2001-11. PubMed ID: 23787814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma.
    Cheng CT; Chu YY; Yeh CN; Huang SC; Chen MH; Wang SY; Tsai CY; Chiang KC; Chen YY; Ma MC; Liu CT; Chen TW; Yeh TS
    Onco Targets Ther; 2015; 8():1899-907. PubMed ID: 26251613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy.
    Montori M; Scorzoni C; Argenziano ME; Balducci D; De Blasio F; Martini F; Buono T; Benedetti A; Marzioni M; Maroni L
    J Clin Med; 2022 Nov; 11(21):. PubMed ID: 36362726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.
    Raggi C; Correnti M; Sica A; Andersen JB; Cardinale V; Alvaro D; Chiorino G; Forti E; Glaser S; Alpini G; Destro A; Sozio F; Di Tommaso L; Roncalli M; Banales JM; Coulouarn C; Bujanda L; Torzilli G; Invernizzi P
    J Hepatol; 2017 Jan; 66(1):102-115. PubMed ID: 27593106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
    Lurje G; Bednarsch J; Czigany Z; Lurje I; Schlebusch IK; Boecker J; Meister FA; Tacke F; Roderburg C; Den Dulk M; Gaisa NT; Bruners P; Neumann UP
    Eur J Surg Oncol; 2019 Aug; 45(8):1468-1478. PubMed ID: 31053477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
    Høgdall D; Lewinska M; Andersen JB
    Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms.
    Roy S; Glaser S; Chakraborty S
    Front Med (Lausanne); 2019; 6():293. PubMed ID: 31921870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
    Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F
    BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.
    Vaquero J; Guedj N; Clapéron A; Nguyen Ho-Bouldoires TH; Paradis V; Fouassier L
    J Hepatol; 2017 Feb; 66(2):424-441. PubMed ID: 27686679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.